Navigation Links
BioClinica, Inc. to Demonstrate Technology-Enhanced Capabilities at Upcoming Global Industry Events
Date:4/3/2013

atory agencies about how multiregional clinical trial (MRCT) data should be utilized and reviewed in new drug applications. MRCTs in East Asia, including Japan, China, Korea, and Taiwan, are now considered one of the promising key strategic options in new drug development. As understanding has deepened through experience with these trials, it is important that industry, governments, and academia come together to discuss and resolve outstanding issues and make improvements in collaboration internationally to activate new drug development in Asia. The conference will include constructive discussions, keynote speeches, and interactive workshops on this important topic. BioClinica representatives will be on hand to demonstrate the company's Imaging Core Lab and Cardiac Safety monitoring services.  

Partnerships in Clinical Trials 
April 21 – 24, 2013
Orlando, Florida
Booth #513
Billed as "the world's most authentic gathering on collaborating for clinical trial excellence," Partnerships in Clinical Trials is the premiere meeting for senior level decision makers across the globe. This year's agenda guarantees to equip attendees with strategies to innovate the clinical trial landscape, a platform to establish essential relationships, and the means to push business forward. The conference will feature three tracks: patient-centered clinical trials, partnering for success in virtual research and development, and cost and contract management. It will also include a strategy summit for small to midsized pharmaceutical and biotechnology companies. BioClinica representatives will attend the conference to demonstrate the company's industry-leading eClinical solutions and Imaging Core Lab and Cardiac Safety services. 

Global Clinical Supplies Group 
April 21
'/>"/>

SOURCE BioClinica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
4. PLC to Demonstrate RenalGuard® at EuroPCR 2012
5. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
6. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
7. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
8. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
9. Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
10. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
11. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... COSTA MESA, Calif. , July 25, 2014 /PRNewswire-iReach/ ... Peter Nieto as the new Vice President ... industry for over 30 years in a number of ... CROs in the industry. These positions were primarily related ... has obtained over the past 30 years makes him ...
(Date:7/25/2014)... OF SPAIN, Trinidad and Tobago , July ... Division of the Trinidad & Tobago Ministry of ... market, an innovative therapy that significantly increases the cure ... for patients infected with the genotype 1 virus. ... under the trade brand INCIVO®. ...
(Date:7/25/2014)... Group Inc (OTC: SLNX) is pleased to announce that ... the Letter of Intent issued on July 11, 2014 ... Charles R. Shirley , Managing Director ... David Pecoraro and Buzznbrewz.com join SLNX,s team.  ... and developed a tremendous network of contacts who have ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... The report, “Glass Fiber & Glass Fiber Reinforced ... Manufacturing Process, By Application (Transportation, Construction, Electrical & ... Trends & Forecast to 2019”, defines and segments ... and forecast by value and volume. , Browse ... through 347 slides and in-depth TOC on "GFRP ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... TUCSON, Ariz., Nov. 25 ... announced that its LogistiCare subsidiary, the nation,s largest coordinator ... award from the State of Florida Commission for the ... both Miami-Dade and Volusia Counties. The award, estimated ...
... , - Agreement Provides Financial Flexibility, Allowing ... Quebec, Nov. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... standby equity distribution agreement (SEDA) with YA Global Master SPV ... terms of the agreement, YA has committed to provide up ...
... and other greenhouse emissions will have major direct health ... change, especially in low-income countries, according to a series ... the British journal The Lancet . Two ... Kirk R. Smith, professor of global environmental health, and ...
... ... sinusitis. A clinically proven, minimally invasive technology for treating chronic sinus inflammation is available ... a small catheter and balloon to quickly open and expand blocked sinuses. , ... (Vocus) November 25, 2009 ...
... ... be offering $100 off every memory foam and latex sofa bed mattress + an additional ... code “BLACKFRIDAY” in the shopping cart to take advantage of this special offer. , ... (PRWEB) November 25, 2009 -- Millions ...
... ... your Emergency Department,s management of seasonal and pandemic novel H1N1 influenza cases this season? ... Which - if any - antiviral should you prescribe? EB Medicine announces its November ... resources on influenza diagnosis and treatment. , ...
Cached Medicine News:Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 2Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 3
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Liquichek Serum Volatiles Control is a bilevel liquid control with assayed values for the most widely measured volatile compounds....
... Urine Control contains a comprehensive ... that monitor tests for general ... hormones. It also contains hCG ... microalbumin at levels suitable for ...
Medicine Products: